1h Free Analyst Time
The acute myeloid leukemia (aml) treatment market in apac is forecasted to grow by USD 393.7 million during 2025-2030, accelerating at a CAGR of 14.1% during the forecast period. The report on the acute myeloid leukemia (aml) treatment market in apac provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by demographic evolution and rising incidence of hematological malignancies, technological advancements in targeted therapies and precision diagnostics, harmonization and enhanced healthcare access via policy reforms.
The study identifies the increasing integration of ai and ml in diagnostic workflows as one of the prime reasons driving the acute myeloid leukemia (aml) treatment market in apac growth during the next few years. Also, strategic shift toward oral hypomethylating agents and outpatient care models and expansion of biosimilar adoption and diversification therapeutic will lead to sizable demand in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The acute myeloid leukemia (aml) treatment market in apac is segmented as below:
By Type
- Chemotherapy
- Stem cell transplantation
- Others
By End-User
- Hospitals and clinics
- Specialty centers
- Ambulatory care centers
- Homecare setting
By Route Of Administration
- Parenteral
- Oral
By Region
- APAC
The report covers the following areas:
- Acute myeloid leukemia (aml) treatment market in apac sizing
- Acute myeloid leukemia (aml) treatment market in apac forecast
- Acute myeloid leukemia (aml) treatment market in apac industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by End-user
10 Market Segmentation by Route of Administration
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global acute myeloid leukemia (aml) treatment market in apac: Agios Inc., Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals Inc., Bristol Myers Squibb Co., Cyclacel Pharmaceuticals Inc., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Jazz Pharmaceuticals Plc, Johnson and Johnson Services, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing integration of ai and ml in diagnostic workflows."
According to the report, one of the major drivers for this market is the demographic evolution and rising incidence of hematological malignancies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agios Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Astex Pharmaceuticals Inc.
- Bristol Myers Squibb Co.
- Cyclacel Pharmaceuticals Inc.
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- F. Hoffmann La Roche Ltd.
- Jazz Pharmaceuticals PLC
- Johnson and Johnson Services
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Ltd.
